EGFR and esophageal squamous cell carcinoma: However, even in this biomarker-selected subgroup of ESCC, significant proportions of patients do not respond to EGFR inhibitors and durable responses are uncommon, indicating that primary and acquired clinical resistance is a major clinical challenge.